Welcome to LookChem.com Sign In|Join Free

CAS

  • or

23593-75-1

Post Buying Request

23593-75-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

23593-75-1 Usage

Broad-spectrum antifungal drug

Clotrimazole is an artificially synthetic azole antifungal agent with inhibitory effect on a variety of pathogenic fungi. It is also able to directly kill the fungi at high concentration. Clotrimazole, through interfering with cytochrome P450 activity, inhibits the biosynthesis of the fungal ergosterol and other steroids; cause damage of the fungal cell membrane and change its permeability, causing the leakage of many kinds of important material in the cell; it can also inhibit the biosynthesis of the fungal triglyceride and phosphor-lipid; the product can still inhibit the activity of oxidase and peroxidase, causing the over-accumulation of peroxides in the cell, causing the degeneration and necrosis of the fungal subcellular structures. Clotrimazole has broad-spectrum antifungal activity with excellent anti-fungal activity against Epidermophyton, Trichophyton, aspergillosis, coloring fungi, Cryptococcus and Candida species. It also has certain antifungal effect against sporothrix schenckii,blastomycosis dermatitidis, Blastomyces coccidioides as well as Histoplasma. It has good anti-fungal effect against Candida, Cryptococcus, Aspergillus, algae bacteria, dermatophytes, etc in both in vivo and in vitro. It efficacy in treating skin superficial mycoses is similar as griseofulvin while its efficacy in treating deep fungal disease is similar as amphotericin B. It has excellent efficacy in treating visceral pathogenic fungi such as Candida albicans, Cryptococcus neoformans, coccidioidomycosis and histoplasma. Its effect on the Candida albicans is stronger than nystatin. Fungi are not easy to evolve drug resistance to this kind of product. This product is easily absorbed orally and can be used for the treatment of systemic fungal infection such as aspergillosis fumigatus, candidiasis, cryptococcosis, coccidioidomycosis, histoplasmosis (dogs, cats) and fungal septicemia. For severe fungal infection, it is preferably to use it in combination with amphotericin B. Topically it can also be used for the treatment of superficial fungal infections such as ringworm and livestock comb body and hair tinea. However, it is invalid in treating tinea capitis. Clotrimazole also has certain efficacy in treating some kinds of Gram-positive bacteria and Trichomonas vaginalis.

Pharmacokinetics

This product is rarely absorbed after oral administration. Adult, after oral administration of 3, has the peak of the plasma concentration being only 1.29 mg/L at 2 hour while 0.78 mg/L at 6 hours. Upon continuous administration, because of the induction effect of liver enzymes, the serum concentration can in turn decrease. The elimination half-life is 4.5 to 6 hours. Most of the products is metabolic inactivated in the liver and is further excreted by bile with only a small amount (less than 1% of dose) being subject to urine excretion in its prototype. The urine excrete were mostly inactive metabolites. This product is presented at high concentration in the feces including the non-absorption part of oral administration as well as the fraction via biliary excretion. Clotrimazole is widely distributed in the body with high concentration existing in the liver and adipose tissue. It can’t penetrate normal meninges and get into the cerebrospinal fluid. This product has a serum protein binding rate of 50%.

Clinical application

Clinical topical usage of 1% clotrimazole cream or solution for treating candidiasis ringworm, tinea versicolor, athlete's foot, nail ringworm and other skin infections. Clotrimazole vaginal tablets (100mg) administration can be used for treating candidiasis and trichomoniasis vaginal infections. Side effects include local irritation and burning sensations. Oral administration can be used for the treatment of deep fungal infection but with serious side effects such as gastrointestinal irritation, neutropenia, and liver function abnormalities. 1. Oral administration: (1) can be used for the treatment of oropharyngeal candidiasis. (2) it can also be used for chemotherapy and the prevention of the oropharynegeal candidiasis infection of immunocompromised or defect patients. 2. Topical: (1) skin candidiasis. (2) Tinea, jork itch and ringworm caused by Trichophyton, Epidermophyton and small spores; tinea versicolor caused by Pityrosporum. 3. Vaginal administration: (1) Vaginitis induced by Candida or other fungi. (2) vaginal infection caused by yeast. (3) Vagina super-infection caused by susceptible strains of the drug. The above information is edited by the lookchem of Dai Xiongfeng.

Mechanism

1. Through reducing the activity of cytochrome P450, it inhibit the biosynthesis of ergosterol and other sterols contained in the fungal cell membrane, causing damage of the fungal cell membrane and change its permeability and causing important intracellular material leakage. 2. Clotrimazole can inhibit the biosynthesis of the fungal triglyceride and phospholipid. 3. It can still inhibit the activity of oxidase and peroxidase, leading to the over-accumulation of hydrogen peroxide inside the cell, causing fungal subcellular structures degeneration and necrosis. 4. For Candida albicans, clotrimazole can suppresses the process of its conversion from spores into invasive hyphae.

Drug Interactions

1, the drug can inhibit the metabolism of drugs like sirolimus and dofetilide mediated by cytochrome P450 3A4 so that the plasma concentration of these drugs increases. 2, when being used in combination with tacrolimus and acamprosate, it can slow down the metabolism of these drugs and increasing its toxicity. 3, when clotrimazole is used in combination with betamethasone, it can make the skin be vulnerable to infection and increase the opportunities for microbial growth; the possible mechanism is through inhibiting the local inflammation. 4, when being used in combination with nystatin, amphotericin B and flucytosine, no synergistic antibacterial effect has been observed for inhibiting Candida albicans; moreover, it has antagonism effect in pharmacodynamic when being used in combination with amphotericin B.

Side effects

1, Oral administration: (1) gastrointestinal reactions: including loss of appetite, nausea, vomiting, abdominal pain and diarrhea. (2) Liver toxicity: Because most of clotrimazole is subjecting to liver metabolism, it can lead to liver damage and causing increased level of serum bilirubin, alkaline phosphatase and aminotransferase. These symptoms can resume after drug withdrawal. (3) There are occasionally transient neuropsychiatric disorders, manifested as depression, hallucinations and disorientation and so on. Once such reactions occur, treatment must be immediately discontinued. (4) There may be occasionally leukopenia. (5) Some patients, after taking the drug, can get a burning sensation in the urethra. At this time, you should drink more water to ensure a high urine output. However, there is no need for stopping the drug. 2, Topical administration may occasionally cause local irritation, itching or burning sensation. Skin can get erythema, papules, vesicles, scaling and so on. There is also report about contact dermatitis. 3, a small amount of vaginal administrators may get vaginal burning sensation, abdominal cramping, and bloating, frequent urination and so on. There may also be varying degrees of allergic reactions such as skin redness and itching, shortness of breath, hypotension or transient feeling, nausea and diarrhea.

Administration instructions

1, the drug can’t be used for systemic fungal infections. Owing to the poor oral absorption of the drug, adverse reactions are common while now we mostly apply topical or vaginal administration. 2, upon using this drug, you should avoid eye contact with the drug. 3, clotrimazole vaginal tablets should be prohibited through oral administration. 4, Administration of the tablets of this product once should overall take 15 to 30 minutes to allow the drug being slowly and completely dissolved. You should avoid chewing or swallowing whole tablet. 5, virginal treatment should be prohibited during menstruation. 6. if there are temporary neuropsychiatric disorder, severe gastrointestinal reactions and local skin allergic reaction happening, you should discontinue the drug immediately.

Chemical Properties

Different sources of media describe the Chemical Properties of 23593-75-1 differently. You can refer to the following data:
1. It is white powder or colorless crystalline powder. It has a melting point of 147-149 ℃. It is soluble in ethanol, acetone, and chloroform, but almost insoluble in water. It is odorless, tasteless and subject to rapid decomposition in an acid solution. Clotrimazole hydrochloride has a m.p. of 159 ℃.
2. White or pale yellow, crystalline powder.

Production method

It can be obtained from o-benzoic acid via esterification, addition, hydrolysis, chlorination, and condensation. It may also be obtained by chlorination of o-chlorotoluene into o-chloro benzotrichloride, which, in the presence of aluminum chloride, has condensation reaction with benzene to generate diphenyl-(2-chlorophenyl) methyl chloride, which finally has condensation reaction with imidazole to obtain clotrimazole.

Description

Clotrimazole is an imidazole antifungal that is active against a wide variety of fungal forms and is effective in many types of fungal infections. It tightly binds sterol 14-α demethylase isoform B from A. fumigatus (KD = 103 nM) and, like other imidazoles, disturbs the fungal cell membrane. In mammalian cells, clotrimazole potently inhibits the calcium-dependent potassium channels Kv1.3 and IK-1 (IC50 = 6.0 and 0.07 μM, respectively).

Originator

Canesten,Bayer,UK,1973

Uses

Different sources of media describe the Uses of 23593-75-1 differently. You can refer to the following data:
1. Clotrimazole is an antifungal agent.
2. An antifungal compound and CYP inhibitor. Clotrimazole (Lotrimin, Mycelex, etc.) is a synthetic imidazole agent. It acts by altering cell membrane permeability. It inhibits the growth of most dermatophyte species, yeast and Malassezia furfur.
3. Clotrimazole formally also is an imidazole derivative because of the presence of an imidazole ring in its structure. It is believed that, like miconazole, econazole, and other “pure” representatives of the imidazole class, it also inhibits the biosynthesis of ergosterin in the cytoplasmatic membrane of fungi. In terms of pharmacological action, clotrimazole is very similar to miconazole. It has a broad spectrum of antifungal activity. It is effective with respect to dermatophytes, and it also has an antimicrobial effect against streptococci and staphylococci. It is also effective with respect to trichomonases. It is very widely used, both externally and vaginally for treating superficial infections. Synonyms of this drug are canesten, empecid, lotrimin, micosporin, and others.

Definition

ChEBI: A member of the class of imidazoles that is 1H-imidazole in which the hydrogen attached to a nitrogen is replaced by a monochlorotrityl group.

Indications

Clotrimazole (Lotrimin, Gyne-Lotrimin, Mycelex) is a broad-spectrum fungistatic imidazole drug used in the topical treatment of oral, skin, and vaginal infections with C. albicans. It is also employed in the treatment of infections with cutaneous dermatophytes. Topical use results in therapeutic drug concentrations in the epidermis and mucous membranes; less than 10% of the drug is systemically absorbed. Although clotrimazole is generally well tolerated, local abdominal cramping, increased urination, and transient liver enzyme elevations have been reported.

Manufacturing Process

156.5 g (0.5 mol) o-chlorophenyldiphenylmethyl chloride and 34 g (0.5 mol) imidazole are dissolved in 500 ml acetonitrile, with stirring, and 51 g (0.5 mol) triethylamine are added, whereupon separation of triethylamine hydrochloride occurs even at room temperature. In order to complete the reaction, heating at 50°C is carried out for 3 hours. After cooling, one liter of benzene is added and the reaction mixture is stirred, then washed salt-free with water. The benzene solution is dried over anhydrous sodium sulfate, filtered and concentrated by evaporation; giving 167 g crude 1-(ochlorophenylbisphenylmethyl)-imidazole. By recrystallization from acetone, 115 g (= 71% of the theory) of pure 1-(o-chlorophenylbisphenylmethyl)- imidazole of MP 154° to 156°C are obtained.

Brand name

Gyne- Lotrimin (Schering-Plough); Gynix (Teva); Lotrimin (Schering-Plough); Mycelex (Bayer).

Therapeutic Function

Antifungal

General Description

Chemical structure: imidazole

Biochem/physiol Actions

Clotrimazole is a specific inhibitor of Ca2+-activated K+ channels. It is an antifungal azole. Clotrimazole is a derivative of imidazole and has similar antimicrobial action and activity to ketoconazole. It inhibits cytochrome P450-dependent 14α-demethylase, which is critical to ergosterol biosynthesis. The accumulated 14α-methylated sterols change the membrane structure of sensitive fungi, altering cell membrane permeability.

Clinical Use

1-(o-Chloro-α,α-diphenylbenzyl)imidazole (Lotrimin, Gyne-Lotrimin, Mycelex) is a broad-spectrum antifungal drug thatis used topically for the treatment of tinea infections and candidiasis.It occurs as a white crystalline solid that is sparinglysoluble in water but soluble in alcohol and most organic solvents.It is a weak base that can be solubilized by dilute mineralacids.Clotrimazole is available as a solution in polyethyleneglycol 400, a lotion, and a cream in a concentration of 1%.These are all indicated for the treatment of tinea pedis, tineacruris, tinea capitis, tinea versicolor, or cutaneous candidiasis.A 1% vaginal cream and tablets of 100 mg and 500 mgare available for vulvovaginal candidiasis. Clotrimazole isextremely stable, with a shelf life of more than 5 years.

Synthesis

Clotrimazole, 1-(o-chloro-α,α-diphenylbenzyl)imidazole (35.2.21), is synthesized by reacting 2-chlorotriphenylmethylchloride (35.2.20) with imidazole in the presence of triethylamine. The starting substance 2-chlorotriphenylmethylchloride is made in various ways. In particular, chlorinating 2-chlorotoluene under light makes 2-chlorotrichloromethylbenzene (35.2.22), which is reacted with benzene in the presence of aluminum chloride to give 2-chlorotriphenylmethylchloride (35.2.20). An alternative way of making 2-chlorotriphenylmethylchloride is a Grignard reaction between 2-chlorobenzolphenone and phenylmagnesium bromide, followed by substitution of the hydroxyl group in the resulting 2-chlorotriphenylmethylcarbinol (35.2.23) with a chlorine using thionyl chloride. And finally, reacting phosphorous pentachloride with 2-chlorobenzophenone gives 2- chloro-1,1-dichlorodiphenylmethane (35.2.24), which is used for the alkylation of benzene in the presence of aluminum chloride and gives 2-chlorotriphenylmethylchloride (35.2.20).

Veterinary Drugs and Treatments

Topical clotrimazole has activity against dermatophytes and yeasts; it may be useful for localized lesions associated with Malassezia. It is not very effective in treating dermatophytosis in cats. Clotrimazole inhibits the biosynthesis of ergosterol, a component of fungal cell membranes leading to increased membrane permeability and probable disruption of membrane enzyme systems.

Check Digit Verification of cas no

The CAS Registry Mumber 23593-75-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,3,5,9 and 3 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 23593-75:
(7*2)+(6*3)+(5*5)+(4*9)+(3*3)+(2*7)+(1*5)=121
121 % 10 = 1
So 23593-75-1 is a valid CAS Registry Number.
InChI:InChI=1/C22H17ClN2/c23-21-14-8-7-13-20(21)22(25-16-15-24-17-25,18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-17H

23593-75-1 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (C2867)  Clotrimazole  >98.0%(HPLC)(T)

  • 23593-75-1

  • 5g

  • 340.00CNY

  • Detail
  • TCI America

  • (C2867)  Clotrimazole  >98.0%(HPLC)(T)

  • 23593-75-1

  • 25g

  • 990.00CNY

  • Detail
  • Sigma-Aldrich

  • (33894)  Clotrimazole  VETRANAL, analytical standard

  • 23593-75-1

  • 33894-100MG-R

  • 586.17CNY

  • Detail
  • Sigma-Aldrich

  • (C2430000)  Clotrimazole  European Pharmacopoeia (EP) Reference Standard

  • 23593-75-1

  • C2430000

  • 1,880.19CNY

  • Detail
  • Sigma-Aldrich

  • (Y0000849)  Clotrimazole for peak identification  European Pharmacopoeia (EP) Reference Standard

  • 23593-75-1

  • Y0000849

  • 1,880.19CNY

  • Detail
  • Sigma

  • (C6019)  Clotrimazole  

  • 23593-75-1

  • C6019-5G

  • 885.69CNY

  • Detail
  • Sigma

  • (C6019)  Clotrimazole  

  • 23593-75-1

  • C6019-25G

  • 3,031.47CNY

  • Detail
  • Sigma

  • (C6019)  Clotrimazole  

  • 23593-75-1

  • C6019-100G

  • 7,716.15CNY

  • Detail

23593-75-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name clotrimazole

1.2 Other means of identification

Product number -
Other names 1-[(2-Chlorophenyl)diphenylmethyl]imidazole

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:23593-75-1 SDS

23593-75-1Synthetic route

1H-imidazole
288-32-4

1H-imidazole

diphenyl phosphite
102-10-3

diphenyl phosphite

o-chlorotriphenylmethanol
66774-02-5

o-chlorotriphenylmethanol

4-methyl-2-pentanone
108-10-1

4-methyl-2-pentanone

clotrimazole
23593-75-1

clotrimazole

Conditions
ConditionsYield
With sodium hydroxide100%
With sodium hydroxide77%
1H-imidazole
288-32-4

1H-imidazole

2-chlorotrityl chloride
42074-68-0

2-chlorotrityl chloride

clotrimazole
23593-75-1

clotrimazole

Conditions
ConditionsYield
With sodium carbonate at 25℃; for 48h; Reagent/catalyst; Solvent; Concentration; Green chemistry;92%
With sodium carbonate at 20℃; for 48h; Sealed tube;92%
With triethylamine In acetonitrile Heating;
With triethylamine In toluene at 20 - 50℃; for 3h; Temperature; Solvent; Inert atmosphere;
1H-imidazole
288-32-4

1H-imidazole

diphenyl phosphite
102-10-3

diphenyl phosphite

o-chlorotriphenylmethanol
66774-02-5

o-chlorotriphenylmethanol

clotrimazole
23593-75-1

clotrimazole

Conditions
ConditionsYield
In toluene74.5%
In acetonitrile; benzene73%
o-chlorotriphenylmethanol
66774-02-5

o-chlorotriphenylmethanol

clotrimazole
23593-75-1

clotrimazole

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: thionyl chloride / Heating
2: triethylamine / acetonitrile / Heating
View Scheme
clotrimazole
23593-75-1

clotrimazole

4-((1,3-bis(dodecanoyloxy)propan-2-yl)oxy)-4-oxobutanoic acid
150994-84-6

4-((1,3-bis(dodecanoyloxy)propan-2-yl)oxy)-4-oxobutanoic acid

4-((1,3-bis(dodecanoyloxy)propan-2-yl)oxy)-4-oxobutanoate 1-((2-chlorophenyl)diphenylmethyl)-1H-imidazol-3-ium

4-((1,3-bis(dodecanoyloxy)propan-2-yl)oxy)-4-oxobutanoate 1-((2-chlorophenyl)diphenylmethyl)-1H-imidazol-3-ium

Conditions
ConditionsYield
In acetonitrile at 50℃; for 6h;100%
clotrimazole
23593-75-1

clotrimazole

o-chlorotriphenylmethanol
66774-02-5

o-chlorotriphenylmethanol

Conditions
ConditionsYield
With hydrogenchloride for 2h; Heating;93%
With hydrogenchloride; water for 3h; Heating / reflux;85%
With hydrogenchloride In water; isopropyl alcohol for 17h; Heating;36%
potassium hexafluorophosphate
17084-13-8

potassium hexafluorophosphate

cis-{Ru(Bipy)(Dppe)Cl2}

cis-{Ru(Bipy)(Dppe)Cl2}

clotrimazole
23593-75-1

clotrimazole

[RuCl(1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole)(1,2-bis(diphenylphosphino)ethane)(2,2′-bypiridine)]*hexafluorophosphate

[RuCl(1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole)(1,2-bis(diphenylphosphino)ethane)(2,2′-bypiridine)]*hexafluorophosphate

Conditions
ConditionsYield
Stage #1: potassium hexafluorophosphate; cis-{Ru(Bipy)(Dppe)Cl2} In dichloromethane for 1h; Inert atmosphere;
Stage #2: clotrimazole In dichloromethane for 6h; Reflux; Inert atmosphere;
92%
clotrimazole
23593-75-1

clotrimazole

C22H14(2)H3ClN2

C22H14(2)H3ClN2

Conditions
ConditionsYield
With deuteromethanol; di(tertbutyl)phenylphosphine; silver carbonate at 65℃; for 48h; Inert atmosphere;91%
clotrimazole
23593-75-1

clotrimazole

1-bromomethyl-3,5-difluoro-benzene
141776-91-2

1-bromomethyl-3,5-difluoro-benzene

3-[(2-chloro-phenyl)-diphenyl-methyl]-1-(3,5-difluoro-benzyl)-3H-imidazol-1-ium; bromide

3-[(2-chloro-phenyl)-diphenyl-methyl]-1-(3,5-difluoro-benzyl)-3H-imidazol-1-ium; bromide

Conditions
ConditionsYield
In ethyl acetate for 48h; Heating;90%
potassium hexafluorophosphate
17084-13-8

potassium hexafluorophosphate

dichloro[1,4-bis(diphenylphosphino)butane](2,2'-bipyridine)ruthenium(II)
200358-34-5, 200259-33-2

dichloro[1,4-bis(diphenylphosphino)butane](2,2'-bipyridine)ruthenium(II)

clotrimazole
23593-75-1

clotrimazole

[RuCl(1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole)(1,4-bis(diphenylphosphino)butane)(2,2′-bypiridine)]*hexafluorophosphate

[RuCl(1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole)(1,4-bis(diphenylphosphino)butane)(2,2′-bypiridine)]*hexafluorophosphate

Conditions
ConditionsYield
Stage #1: potassium hexafluorophosphate; dichloro[1,4-bis(diphenylphosphino)butane](2,2'-bipyridine)ruthenium(II) In dichloromethane for 1h; Inert atmosphere;
Stage #2: clotrimazole In dichloromethane for 6h; Reflux; Inert atmosphere;
90%
[dichloro(p-cymene)(triphenylphosphane)ruthenium(II)]
52490-94-5

[dichloro(p-cymene)(triphenylphosphane)ruthenium(II)]

clotrimazole
23593-75-1

clotrimazole

hexafluorophosphate salt

hexafluorophosphate salt

[RuCl(clotrimazole)(η6-p-cymene)(PPh3)]PF6

[RuCl(clotrimazole)(η6-p-cymene)(PPh3)]PF6

Conditions
ConditionsYield
In methanol for 8h; Reflux; Inert atmosphere;90%
copper(II) acetate monohydrate
6046-93-1

copper(II) acetate monohydrate

clotrimazole
23593-75-1

clotrimazole

[Cu(clotrimazole)2(Ac)2]*H2O

[Cu(clotrimazole)2(Ac)2]*H2O

Conditions
ConditionsYield
In methanol at 25℃; for 24h;90%
[RhCl2(p-cymene)]2

[RhCl2(p-cymene)]2

clotrimazole
23593-75-1

clotrimazole

[(η6-p-cymene)RuCl(clotrimazole)2]Cl
1581279-26-6

[(η6-p-cymene)RuCl(clotrimazole)2]Cl

Conditions
ConditionsYield
In methanol; chloroform for 5h; Reflux;89%
silver(I) hexafluorophosphate
26042-63-7

silver(I) hexafluorophosphate

[RhCl2(p-cymene)]2

[RhCl2(p-cymene)]2

clotrimazole
23593-75-1

clotrimazole

[(η6-p-cymene)Ru(clotrimazole)3](PF6)2

[(η6-p-cymene)Ru(clotrimazole)3](PF6)2

Conditions
ConditionsYield
In methanol; chloroform for 3h; Reflux;86%
potassium hexafluorophosphate
17084-13-8

potassium hexafluorophosphate

cis-[RuCl2(1,1′-bis(diphenylphosphino)ferrocene)(2,2′-bipyridine)]

cis-[RuCl2(1,1′-bis(diphenylphosphino)ferrocene)(2,2′-bipyridine)]

clotrimazole
23593-75-1

clotrimazole

[RuCl(1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole)(1,1′-bis(diphenylphosphino)ferrocene)(2,2′-bypiridine)]*hexafluorophosphate

[RuCl(1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole)(1,1′-bis(diphenylphosphino)ferrocene)(2,2′-bypiridine)]*hexafluorophosphate

Conditions
ConditionsYield
Stage #1: potassium hexafluorophosphate; cis-[RuCl2(1,1′-bis(diphenylphosphino)ferrocene)(2,2′-bipyridine)] In dichloromethane for 1h; Inert atmosphere;
Stage #2: clotrimazole In dichloromethane for 6h; Reflux; Inert atmosphere;
86%
copper(II) nitrate trihydrate

copper(II) nitrate trihydrate

clotrimazole
23593-75-1

clotrimazole

[Cu(clotrimazole)2(H2O)(NO3)](NO3)*2H2O

[Cu(clotrimazole)2(H2O)(NO3)](NO3)*2H2O

Conditions
ConditionsYield
In methanol at 25℃; for 24h;84%
clotrimazole
23593-75-1

clotrimazole

triphenylmethane
519-73-3

triphenylmethane

Conditions
ConditionsYield
With tetraethylammonium perchlorate; triethylamine In dimethyl sulfoxide at 20℃; for 24h; Electrolysis; Green chemistry;81%
di-μ-chloro-bis(1,5-cyclooctadiene)dirhodium
12092-47-6

di-μ-chloro-bis(1,5-cyclooctadiene)dirhodium

clotrimazole
23593-75-1

clotrimazole

RhCl(1,5-cyclooctadiene)(1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole)
209979-92-0

RhCl(1,5-cyclooctadiene)(1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole)

Conditions
ConditionsYield
In ethanol N2-atmosphere; stoich. amts., stirring at room temp. for 1 h; collection (filtration), washing (MeOH), drying (vac.); elem. anal.;80%
clotrimazole
23593-75-1

clotrimazole

4-chloro-1-((2-chlorophenyl)diphenylmethyl)-1H-imidazole
1605347-53-2

4-chloro-1-((2-chlorophenyl)diphenylmethyl)-1H-imidazole

Conditions
ConditionsYield
With N-chloro-N-fluoro-benzenesulfonamide In acetonitrile at 20℃; Reagent/catalyst;80%
With N-chloro-N-fluoro-benzenesulfonamide In acetonitrile at 20℃; regioselective reaction;77%
With 2-chloro-1,3-bis(methoxycarbonyl)guanidine In chloroform at 20℃; for 12h; Solvent; regioselective reaction;72%
clotrimazole
23593-75-1

clotrimazole

(bromomethylcyclohexane)
2550-36-9

(bromomethylcyclohexane)

3-[(2-chloro-phenyl)-diphenyl-methyl]-1-cyclohexylmethyl-3H-imidazol-1-ium; bromide

3-[(2-chloro-phenyl)-diphenyl-methyl]-1-cyclohexylmethyl-3H-imidazol-1-ium; bromide

Conditions
ConditionsYield
In ethyl acetate for 48h; Heating;79%
bis(triphenylphosphino)copper(I) nitrate
14494-93-0, 23751-62-4, 106678-35-7

bis(triphenylphosphino)copper(I) nitrate

clotrimazole
23593-75-1

clotrimazole

[Cu(PPh3)2(1-[(2-chlorophenyl)-diphenylmethyl]-1H-imidazole)2]NO3

[Cu(PPh3)2(1-[(2-chlorophenyl)-diphenylmethyl]-1H-imidazole)2]NO3

Conditions
ConditionsYield
In acetonitrile for 24h;79%
C14H20B9(1-)*C4H12N(1+)

C14H20B9(1-)*C4H12N(1+)

clotrimazole
23593-75-1

clotrimazole

C36H36B9ClN2

C36H36B9ClN2

Conditions
ConditionsYield
With 2,3-dicyano-5,6-dichloro-p-benzoquinone In 1,2-dimethoxyethane at 20℃; for 5h; Inert atmosphere; Schlenk technique;78%
water
7732-18-5

water

clotrimazole
23593-75-1

clotrimazole

zinc(II) chloride
7646-85-7

zinc(II) chloride

[ZnCl2(N2C3H3C(C6H5)2C6H4Cl)2(H2O)2]*3H2O

[ZnCl2(N2C3H3C(C6H5)2C6H4Cl)2(H2O)2]*3H2O

Conditions
ConditionsYield
In ethanol; water hot soln. (60 °C) of metal chloride added to hot soln. (60 °C) of CLMZ, mixt. stirred under reflux for 1 h; pptn., filtration, washing (ethanol/water, petroleum ether), elem. anal.;77%
clotrimazole
23593-75-1

clotrimazole

C22H16BrClN2

C22H16BrClN2

Conditions
ConditionsYield
With N-chloro-N-fluoro-benzenesulfonamide; potassium bromide In acetonitrile at 20℃; for 0.25h;77%
clotrimazole
23593-75-1

clotrimazole

methyl iodide
74-88-4

methyl iodide

3-[(2-chloro-phenyl)-diphenyl-methyl]-1-methyl-3H-imidazol-1-ium; iodide

3-[(2-chloro-phenyl)-diphenyl-methyl]-1-methyl-3H-imidazol-1-ium; iodide

Conditions
ConditionsYield
In dichloromethane at 45℃; for 0.25h; Microwave irradiation;75%
In ethyl acetate at 20℃; for 48h;49%
tetrakis(actonitrile)copper(I) hexafluorophosphate
64443-05-6

tetrakis(actonitrile)copper(I) hexafluorophosphate

clotrimazole
23593-75-1

clotrimazole

[Cu(1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole)2]PF6

[Cu(1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole)2]PF6

Conditions
ConditionsYield
In dichloromethane stoich. amts., room temp., 24 h; vol. reduction (N2-stream), Et2O addn., cooling to -5°C (pptn.), collection (filtration), washing (Et2O), drying (vac.); elem. anal.;75%
manganese(II) chloride dihydrate

manganese(II) chloride dihydrate

water
7732-18-5

water

clotrimazole
23593-75-1

clotrimazole

[MnCl2(N2C3H3C(C6H5)2C6H4Cl)2(H2O)2]
1311268-76-4

[MnCl2(N2C3H3C(C6H5)2C6H4Cl)2(H2O)2]

Conditions
ConditionsYield
In ethanol; water hot soln. (60 °C) of metal chloride added to hot soln. (60 °C) of CLMZ, mixt. stirred under reflux for 1 h; pptn., filtration, washing (ethanol/water, petroleum ether), elem. anal.;75%
[RhCl2(p-cymene)]2

[RhCl2(p-cymene)]2

clotrimazole
23593-75-1

clotrimazole

[(η6-p-cymene)RuCl2(clotrimazole)]

[(η6-p-cymene)RuCl2(clotrimazole)]

Conditions
ConditionsYield
In methanol; chloroform at 20℃; for 0.075h; Reflux;75%
zinc(II) nitrate hexahydrate

zinc(II) nitrate hexahydrate

clotrimazole
23593-75-1

clotrimazole

[Zn(clotrimazole)2(H2O)(NO3)](NO3)*4H2O

[Zn(clotrimazole)2(H2O)(NO3)](NO3)*4H2O

Conditions
ConditionsYield
In methanol at 25℃; for 0.5h;74%
clotrimazole
23593-75-1

clotrimazole

C22H13(2)H4ClN2

C22H13(2)H4ClN2

Conditions
ConditionsYield
With water-d2; potassium carbonate; silver carbonate; cyclohexyldiphenylphosphine In toluene at 120℃; for 12h;73%

23593-75-1Relevant articles and documents

Preparation method of clotrimazole

-

Paragraph 0027-0029; 0033-0038; 0042-0048, (2020/07/28)

The invention provides a preparation method of clotrimazole. The preparation method comprises the following steps: step 1, chlorinating (2-chlorphenyl) diphenyl methanol into (2-chlorphenyl) diphenylchloromethane; 2, subjecting (2-chlorphenyl) diphenyl chloromethane and imidazole to condensation to form clotrimazole; the total reaction flow formula is shown in the specification. The invention provides a preparation method of clotrimazole. The initial raw materials (2-chlorphenyl) diphenyl methanol and imidazole are easy to obtain and stable in performance; reaction condition mildness, a product which is unstable when meeting water and synthesized in step 1 does not need to be separated and purified, and can be applied directly in step 2, not only are the requirements on equipment and operation reduced, but also the risk of influencing the quality of the raw material medicine is reduced; the preparation method is simple in operation, short in process period, high in product purity andsuitable for industrial production, , in addition, the reaction solvent in the step 1 is also the reaction solvent in the step 2, emission of three wastes is reduced, and environmental protection is better facilitated.

Fluorinated Alcohol-Promoted Reaction of Chlorohydrocarbons with Diverse Nucleophiles for the Synthesis of Triarylmethanes and Tetraarylmethanes

Yu, Liping,Li, Shuai-Shuai,Li, Weina,Yu, Shitao,Liu, Qing,Xiao, Jian

, p. 15277 - 15283 (2019/01/04)

This article reports an efficient synthesis of triarylmethanes and tetraarylmethanes from chlorohydrocarbons with miscellaneous nucleophiles in fluorinated alcohols, featuring metal-free, wide substrate scope, excellent functional group tolerance, and mild reaction conditions.

Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction

-

, (2008/06/13)

The present invention relates to chemical compounds having inhibitory activity on an intermediate conductance Ca 2+ activated potassium channel (IK Ca), and the use of such compounds for the treatment or alleviation of diseases or conditions relating to immune dysfunction. Moreover, the invention relates to a method of screening a chemical compound for inhibitory activity on an intermediate conductance Ca 2+ activated potassium channel (IK Ca).

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 23593-75-1